HBV reactivation is associated with high mortality rates in hematopoietic stem cell transplantation (HSCT) and prophylactic lamivudine (LMV) treatment is suggested to prevent this phenomenon. However, the duration of LMV treatment in HSCT patients is not fully defined and the time of immune recovery is considered the best parameter for a drug to be safely interrupted. In patients undergoing allogeneic HSCT, the time of immune recovery is not easy to define and may take years after transplantation and prolonged LMV treatments, which can lead to drug-resistant viral strains.

Cerva, C., Maffongelli, G., Svicher, V., Salpini, R., Colagrossi, L., Battisti, A., et al. (2017). Hepatitis B reactivation characterized by HBsAg negativity and anti-HbsAg antibodies persistence in haematopoietic stem cell transplanted patient after lamivudine withdrawal. BMC INFECTIOUS DISEASES, 17(1), 566 [10.1186/s12879-017-2672-6].

Hepatitis B reactivation characterized by HBsAg negativity and anti-HbsAg antibodies persistence in haematopoietic stem cell transplanted patient after lamivudine withdrawal

MAFFONGELLI, GAETANO;SVICHER, VALENTINA;Salpini, R;COLAGROSSI, LUNA;BATTISTI, ARIANNA;CUDILLO, LAURA;SARMATI, LOREDANA
2017-08-15

Abstract

HBV reactivation is associated with high mortality rates in hematopoietic stem cell transplantation (HSCT) and prophylactic lamivudine (LMV) treatment is suggested to prevent this phenomenon. However, the duration of LMV treatment in HSCT patients is not fully defined and the time of immune recovery is considered the best parameter for a drug to be safely interrupted. In patients undergoing allogeneic HSCT, the time of immune recovery is not easy to define and may take years after transplantation and prolonged LMV treatments, which can lead to drug-resistant viral strains.
15-ago-2017
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/17 - MALATTIE INFETTIVE
English
Con Impact Factor ISI
HBV reactivation; Hbv DNA; Hematopoietic stem cell transplantation; Hepatitis B; Prophylaxis
Cerva, C., Maffongelli, G., Svicher, V., Salpini, R., Colagrossi, L., Battisti, A., et al. (2017). Hepatitis B reactivation characterized by HBsAg negativity and anti-HbsAg antibodies persistence in haematopoietic stem cell transplanted patient after lamivudine withdrawal. BMC INFECTIOUS DISEASES, 17(1), 566 [10.1186/s12879-017-2672-6].
Cerva, C; Maffongelli, G; Svicher, V; Salpini, R; Colagrossi, L; Battisti, A; Mariotti, B; Cerretti, R; Cudillo, L; Sarmati, L
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/189632
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 6
social impact